Filtered By:
Management: Medicaid
This page shows you your search results in order of relevance. This is page number 9.
Order by Relevance | Date
Total 217 results found since Jan 2013.
CMS seeks input on future of Open Payments program
The Centers for Medicare & Medicaid Services is seeking physician input on the Open Payments program.
The agency signaled its intent to gather information in its <a...
Source: Skin and Allergy News - July 21, 2016 Category: Dermatology Source Type: news
Comparison of asthma prevalence and morbidity among rural and nonrural youth
Characterizing the experience of pediatric asthma in rural communities is in a nascent stage. Rural youth can encounter barriers that place them at risk for asthma-related health disparities.1 They are also equally2,3 or more likely4 to be diagnosed as having asthma than youth in urban areas and can experience significant asthma morbidity.3 –7 Previous studies have compared rural and urban youth residing in separate states,2 focused on a predominantly minority and low-income sample from a rural south delta region,5–7 or analyzed a Medicaid-only cohort of young rural children.
Source: Annals of Allergy, Asthma and Immunology - June 6, 2016 Category: Allergy & Immunology Authors: David A. Fedele, Tracey E. Barnett, Robin S. Everhart, Casey Lawless, Jamie R. Forrest Tags: Letter Source Type: research
Medicaid expansion leads to better access to care
Low-income adults living in two states that expanded Medicaid enrollment are showing significant increases in outpatient utilization and preventive care, improved health care quality, and reductions in emergency department use, compared with those living in a state that did not expand Medicaid,...
Source: Skin and Allergy News - August 9, 2016 Category: Dermatology Source Type: news
U.S. lawmakers question Mylan's Medicaid EpiPen rebates
(Reuters) - Two key U.S. congressional committee members on Friday called for an investigation into whether Mylan NV, under fire for raising the price of its EpiPen device, overcharged the government's low-income healthcare program for the allergy treatment.
Source: Reuters: Health - September 2, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
ACOs score slight bump in bonus payments
Accountable care organizations participating in the Medicare Shared Savings Program generated $466 million in savings in 2015, up from $411 million in 2014, the Centers for Medicare & Medicaid Services announced.
Despite the growth in savings, there was little growth in the number of ACOs...
Source: Skin and Allergy News - September 7, 2016 Category: Dermatology Source Type: news
Senate Republicans seek probe of Mylan EpiPen oversight
NEW YORK (Reuters) - Mylan NV faced new scrutiny over price hikes for its anti-allergy EpiPen on Tuesday, with U.S. lawmakers calling for a probe of oversight of the company ’s rebates to government healthcare plans, while West Virginia said it was investigating whether Mylan defrauded its Medicaid department.
Source: Reuters: Health - September 21, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
EpiPen price hike cost Pentagon millions
Mylan Pharmaceuticals‘ (NSDQ:MYL) 500% price increase on its epinephrine auto-injector cost the U.S Defense Dept. millions, according to data provided to Reuters.
The Pentagon spent $57 million on Mylan’s EpiPen last year, up from $9 million in 2008, largely driven by volume and price hikes that affected prescriptions filled at retail pharmacies. Although the Pentagon gets a government discount for EpiPens from military treatment facilities and by mail order, nearly half of its spending was at retail pharmacies. Recently, it paid an average of $528 for a two-pack of the lifesaving allergy treatment. That&...
Source: Mass Device - October 31, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Centers for Medicare and Medicaid Services (CMS) Mylan Source Type: news
CMS acting chief Slavitt slams drug pricing
Centers for Medicare & Medicaid Services acting chief Andy Slavitt admonished pharma companies like Mylan (NSDQ:MYL) over unsustainable price increases before the Biopharma Congress in Washington D.C. last week.
Mylan came under fire this year after reports showed that the Canonsburg, Penn.-based company raised the price of its emergency allergy epinephrine injector by 500% since it acquired the product in 2007 from Merck. CEO Heather Bresch pledged to expand the company’s patient assistance program and launch a generic device that will cost $300, half of what a 2-pack of EpiPens costs.
Get the full story ...
Source: Mass Device - November 7, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Business/Financial News Drug-Device Combinations Healthcare Reform Pharmaceuticals Wall Street Beat Centers for Medicare and Medicaid Services (CMS) Mylan Teva Pharmaceuticals Source Type: news
Mylan working to finalize EpiPen Medicaid settlement: CFO
(Reuters) - Generic drugmaker Mylan NV said on Wednesday it was working to finalize a settlement with the U.S. government over Medicaid rebates for its EpiPen emergency allergy treatment, adding that money set aside for the settlement led to a third quarter loss.
Source: Reuters: Health - November 9, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
U.S. Watchdog Told Medicare, Medicaid That EpiPen Was Misclassified in 2009 -Senator U.S. Watchdog Told Medicare, Medicaid That EpiPen Was Misclassified in 2009 -Senator
The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV ' s EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said Tuesday.Reuters Health Information
Source: Medscape Allergy Headlines - November 9, 2016 Category: Allergy & Immunology Tags: Diabetes & Endocrinology News Source Type: news
5 Ways The Zika Virus Is Here To Stay
Zika virus’ status as a global health threat may officially be over, but the disease’s impact is far from contained.
The World Health Organization decided in November to end its designation of Zika virus as a public health emergency, but that doesn’t mean that Zika virus has disappeared, explained Dr. Carlos Pardo-Villamizar, a clinical neurologist with an expertise in infectious disorders at Johns Hopkins Medicine.
Alongside pressing concerns about how to prevent a resurgence of the disease, health care systems in Brazil and other countries that saw births of babies infected with the disease in ute...
Source: Healthy Living - The Huffington Post - January 4, 2017 Category: Consumer Health News Source Type: news
U.S. health agency tells Grassley there is no EpiPen deal yet
NEW YORK (Reuters) - Mylan NV has yet to reach a settlement with the U.S. Department of Justice over the classification in the Medicaid program of its life-saving EpiPen allergy treatment, according to a letter from a regulatory agency disclosed on Thursday.
Source: Reuters: Health - January 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Partisan Jousting Marks Price Hearing for HHS Post
(MedPage Today) -- Medicaid, Medicare and ACA Repeal debated during nominee hearing
Source: MedPage Today Allergy - January 25, 2017 Category: Allergy & Immunology Source Type: news
CMS nominee Verma: Mylan ’ s EpiPen case ‘ disturbing ’
Seema Verma, the nominee to head the Centers for Medicare & Medicaid, said at her confirmation hearing that she would like to review the way pharmaceutical companies classify products as generic or branded, citing the case of Mylan‘s (NSDQ:MYL) EpiPen emergency allergy device.
Mylan faced criticism this year for classifying EpiPen as a generic and paying smaller rebates to Medicaid than if the device was listed as branded.
Get the full story at our sister site, Drug Delivery Business News.
The post CMS nominee Verma: Mylan’s EpiPen case ‘disturbing’ appeared first on MassDevice.
Source: Mass Device - February 17, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Healthcare Reform Pharmaceuticals Wall Street Beat Centers for Medicare and Medicaid Services (CMS) Mylan Source Type: news
